Glucos B. Braun

Glucos B. Braun is an intravenous solution for injection that contains glucose monohydrate as its sole active ingredient. Marketed in the European Union, the product is supplied as a sterile aqueous solution, typically without a specified concentration on the label. It is classified as an excipient used to provide caloric energy and support fluid balance during parenteral therapy, and may be selected when an isotonic carbohydrate source is needed.

Glucos B. Braun is primarily employed as an intravenous carbohydrate source in clinical settings.

- Provide supplemental calories for patients unable to receive oral nutrition. - Maintain blood glucose levels during fasting or surgical procedures. - Serve as a diluent for compatible intravenous medications. - Assist in correcting mild hypoglycemia when rapid glucose delivery is required. - Contribute to fluid replacement in combination with electrolytes.

Adverse reactions to Glucos B. Braun are generally related to the intravenous administration of a glucose solution and may vary in frequency and severity.

Common: - Mild hyperglycemia, especially in patients with impaired glucose tolerance. - Local irritation at the infusion site. - Nausea or vomiting if administered rapidly. - Transient electrolyte shifts, such as mild hyponatremia. - Blood sugar spikes causing temporary fatigue.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Allergic reactions ranging from urticaria to anaphylaxis. - Volume overload in patients with compromised cardiac function. - Hyperosmolar coma in uncontrolled diabetes.

When using Glucos B. Braun, clinicians should observe several precautions to ensure patient safety and appropriate therapeutic effect.

- Assess baseline blood glucose and monitor levels during infusion. - Adjust infusion rate in patients with renal or cardiac insufficiency to avoid fluid overload. - Avoid use in individuals with known hypersensitivity to glucose solutions. - Consider alternative carbohydrate sources for patients with severe hyperglycemia or diabetic ketoacidosis. - Verify compatibility with other intravenous drugs before mixing. - Store the solution according to manufacturer guidelines to maintain sterility.

Glucose solutions can interact with other intravenously administered agents, influencing efficacy or safety.

Avoid: - Co‑administration with high‑dose insulin infusions without appropriate glucose monitoring. - Mixing with calcium‑containing solutions that may precipitate. - Simultaneous infusion of hypertonic saline that could exacerbate hyperglycemia. - Concurrent infusion with potassium chloride solutions, which may cause precipitation.

Use with caution: - Concurrent use of diuretics, which may affect fluid balance and electrolyte status. - Administration alongside beta‑blockers, as they can mask signs of hypoglycemia. - Combining with catecholamines, which may increase glucose production and alter glycemic control. - Use with caution when patients are receiving glucocorticoids, as they can raise blood glucose.